12,427 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd bought a new position in shares of Revvity, Inc. (NYSE:RVTY) in the 4th quarter, Holdings Channel.com reports. The fund bought 12,427 shares of the company’s stock, valued at approximately $1,358,000.

Other large investors have also recently made changes to their positions in the company. KBC Group NV purchased a new position in Revvity in the third quarter worth approximately $25,301,000. 2Xideas AG purchased a new position in Revvity in the third quarter worth approximately $20,968,000. Citigroup Inc. purchased a new position in Revvity in the third quarter worth approximately $5,548,000. Wesbanco Bank Inc. purchased a new position in Revvity in the third quarter worth approximately $522,000. Finally, Headinvest LLC acquired a new stake in Revvity during the third quarter worth approximately $57,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Stock Down 0.8 %

RVTY opened at $102.68 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77. Revvity, Inc. has a 12 month low of $79.50 and a 12 month high of $133.26. The stock has a market capitalization of $12.68 billion, a P/E ratio of 18.67, a P/E/G ratio of 2.69 and a beta of 1.09. The business has a 50 day simple moving average of $104.72 and a 200-day simple moving average of $101.50.

Revvity (NYSE:RVTY) last released its earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.15 by $0.10. The company had revenue of $695.90 million during the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. On average, equities analysts anticipate that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. KeyCorp raised their price objective on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Raymond James boosted their price objective on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Barclays raised their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Evercore ISI upgraded shares of Revvity from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $88.00 to $125.00 in a research note on Thursday, January 4th. Finally, Stifel Nicolaus raised their price objective on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $118.91.

Insiders Place Their Bets

In other news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the completion of the sale, the insider now directly owns 92,801 shares in the company, valued at approximately $9,677,288.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.60% of the stock is currently owned by company insiders.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.